These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35890187)

  • 1. Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report.
    Nishii Y; Furuhashi K; Ito K; Sakaguchi T; Suzuki Y; Fujiwara K; Yasuma T; Kobayashi T; D'Alessandro-Gabazza CN; Gabazza EC; Taguchi O; Hataji O
    Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus
    Araya T; Kita T; Matsuoka H; Sakai T; Kimura H; Kasahara K
    Case Rep Oncol; 2020; 13(3):1506-1512. PubMed ID: 33564291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression.
    Isshiki T; Isobe K; Tochigi N; Sunakawa M; Nakamura Y; Shibuya K; Sakamoto S; Takai Y; Homma S
    Case Rep Oncol; 2018; 11(3):688-692. PubMed ID: 30483099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-Line Treatment with Carboplatin plus
    Funaishi K; Yamasaki M; Saito N; Daido W; Ishiyama S; Deguchi N; Taniwaki M; Ohashi N
    Case Rep Oncol; 2017; 10(2):571-576. PubMed ID: 28868014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
    Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
    Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
    Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
    Langer CJ; Gadgeel SM; Borghaei H; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Ge Y; Raftopoulos H; Gandhi L;
    Lancet Oncol; 2016 Nov; 17(11):1497-1508. PubMed ID: 27745820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robust and durable response to first-line treatment of pembrolizumab combined with chemotherapy in two patients with metastatic thymic squamous cell carcinoma: Case report.
    Chen C; Sun P; Long J
    Front Immunol; 2022; 13():941092. PubMed ID: 35983052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab.
    Sawatari K; Izumi M; Sone R; Hattori T; Sugimoto A; Eguchi Y; Mamoto T
    Respir Med Case Rep; 2022; 36():101579. PubMed ID: 35059287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multidisciplinary approach to treating a unique case of recurrent metastatic thymic carcinoma: case report.
    Wang C; Erick Elkowitz D; Esposito MJ; Shah RD; Tannous H; Barilla-Labarca ML; Seetharamu N
    Ther Adv Rare Dis; 2023; 4():26330040231190661. PubMed ID: 37576433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
    Paz-Ares L; Luft A; Vicente D; Tafreshi A; Gümüş M; Mazières J; Hermes B; Çay Şenler F; Csőszi T; Fülöp A; Rodríguez-Cid J; Wilson J; Sugawara S; Kato T; Lee KH; Cheng Y; Novello S; Halmos B; Li X; Lubiniecki GM; Piperdi B; Kowalski DM;
    N Engl J Med; 2018 Nov; 379(21):2040-2051. PubMed ID: 30280635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A Case of Squamous Cell Lung Cancer in an Elderly Patient with Low PD-L1 Expression Effectively Treated with Nab-Paclitaxel(Nab-PTX)plus Carboplatin (CBDCA)plus Pembrolizumab for a Recurrence after Operation].
    Sakaguchi K; Kosaka M; Yamazaki Y
    Gan To Kagaku Ryoho; 2020 May; 47(5):819-821. PubMed ID: 32408327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful resection after first-line lenvatinib therapy in an advanced thymic carcinoma.
    Shimura M; Miura K; Koizumi T; Kanda S; Mishima S; Hara D; Matsuoka S; Eguchi T; Hamanaka K; Uehara T; Shimizu K
    Thorac Cancer; 2023 Jun; 14(17):1640-1643. PubMed ID: 37132133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study.
    Wu YL; Zhang L; Fan Y; Zhou J; Zhang L; Zhou Q; Li W; Hu C; Chen G; Zhang X; Zhou C; Dang T; Sadowski S; Kush DA; Zhou Y; Li B; Mok T
    Int J Cancer; 2021 May; 148(9):2313-2320. PubMed ID: 33231285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
    Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V
    Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab Plus Chemotherapy in Metastatic Thymic Carcinoma: A Case Report.
    Thomas QD; Basse C; Luporsi M; Girard N
    Front Oncol; 2021; 11():814544. PubMed ID: 35127529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histologic transformation of lung cancer during pembrolizumab therapy: A case report.
    Si X; You Y; Zhang X; Wang H; Wang M; Zhang L
    Thorac Cancer; 2020 Mar; 11(3):793-796. PubMed ID: 31944570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
    Gadgeel SM; Stevenson JP; Langer CJ; Gandhi L; Borghaei H; Patnaik A; Villaruz LC; Gubens M; Hauke R; Yang JC; Sequist LV; Bachman R; Saraf S; Raftopoulos H; Papadimitrakopoulou V
    Lung Cancer; 2018 Nov; 125():273-281. PubMed ID: 30429032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to chemotherapy with carboplatin plus albumin-bound paclitaxel in a patient with lymphoepithelioma-like thymic carcinoma: A case report.
    Shima H; Ozasa H; Tsuji T; Ajimizu H; Nomizo T; Yagi Y; Sakamori Y; Nagai H; Minamiguchi S; Kim YH; Mishima M
    Mol Clin Oncol; 2016 May; 4(5):715-718. PubMed ID: 27123268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.